Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) Net Income towards Common Stockholders: 2012-2025

Historic Net Income towards Common Stockholders for Ptc Therapeutics (PTCT) over the last 14 years, with Sep 2025 value amounting to $15.9 million.

  • Ptc Therapeutics' Net Income towards Common Stockholders rose 114.90% to $15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $751.7 million, marking a year-over-year increase of 265.87%. This contributed to the annual value of -$363.3 million for FY2024, which is 42.02% up from last year.
  • Per Ptc Therapeutics' latest filing, its Net Income towards Common Stockholders stood at $15.9 million for Q3 2025, which was up 124.51% from -$64.8 million recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Net Income towards Common Stockholders registered a high of $866.6 million during Q1 2025, and its lowest value of -$198.9 million during Q2 2023.
  • Over the past 3 years, Ptc Therapeutics' median Net Income towards Common Stockholders value was -$99.2 million (recorded in 2024), while the average stood at -$15.7 million.
  • Per our database at Business Quant, Ptc Therapeutics' Net Income towards Common Stockholders crashed by 91.74% in 2021 and then skyrocketed by 1,046.28% in 2025.
  • Quarterly analysis of 5 years shows Ptc Therapeutics' Net Income towards Common Stockholders stood at -$143.3 million in 2021, then fell by 19.28% to -$170.9 million in 2022, then grew by 8.83% to -$155.8 million in 2023, then surged by 57.71% to -$65.9 million in 2024, then surged by 114.90% to $15.9 million in 2025.
  • Its Net Income towards Common Stockholders was $15.9 million in Q3 2025, compared to -$64.8 million in Q2 2025 and $866.6 million in Q1 2025.